Thomas Loewald, senior vice president and chief commercial officer at Thermo Fisher Scientific since early 2016, will resign from the company, effective Sept. 1. He joined the firm's explosives detection business in 2002 and held various positions over the years, including senior vice president and president of laboratory products. Prior to that, he was vice president of sales and marketing for Tyco International.
Gene DeFelice and Alexandra Snyder
Adaptive Biotechnologies has appointed Gene DeFelice as senior vice president and general counsel, and Alexandra Snyder as translational medicine lead for adaptive research. DeFelice has served as general counsel for several public healthcare and technology companies, including as primary counsel at Roche Diagnostics. He will join Adaptive's executive team to implement a legal infrastructure for clinical applications of next-generation sequencing technologies. Snyder has joined Adaptive from Memorial Sloan Kettering Cancer Research Center where she specialized in tumor immunogenomics and response to checkpoint blockade immunotherapy.
Cynthia Bens will join the Personalized Medicine Coalition as vice president of public policy effective Aug. 21. Bens comes to PMC after more than a decade with the Alliance for Aging Research where she helped advocate for policies, including the 21st Century Cures Act, the Prescription Drug User Fee Act, and the FDA's Patient-Focused Drug Development initiative. Prior to that, she spent four years at the bipartisan government affairs firm the Loeffler Group and also worked as a staff assistant on Capitol Hill.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.